Parkinson's disease psychosis drug Nuplazid granted FDA priority review
The FDA has granted priority review of Acadia Pharmaceuticals' new drug application (NDA) for Nuplazid (pimavanserin) that is intended to treat Parkinson's disease psychosis. Read More »